Background. Toxoplasma infection during pregnancy exposes the fetus to risks of congenital infection and sequelae that depend heavily on gestational age (GA) at time of infection. Accurate risk estimates by GA are necessary to counsel parents and improve clinical decisions.
Maternal acquisition of Toxoplasma gondii infection during pregnancy exposes the fetus to a risk of congenital infection through transplacental transmission of the parasite. Incidence and severity depend on gestational age (GA) at the time of maternal infection. In early pregnancy, congenital infection is rare but can lead to miscarriages, stillbirths, or the birth of children with signs of central nervous system involvement, such as hydrocephalus, meningoencephalitis, and retinochoroiditis [1] [2] [3] . When primary maternal infection occurs in the latter half of pregnancy, congenital infection is more frequent but manifestations in the infant are less severe. However, retinochoroiditis can appear and relapse anytime after birth [4] [5] [6] [7] [8] [9] .
For several decades, attempts have been made to obtain risk estimates for maternofetal transmission rates and for severity of congenital infection according to GA at maternal infection, which can be used for individual patient management and for assessment of preventive interventions [10] [11] [12] [13] [14] [15] . Only a few studies fulfilled the required methodological criteria: large series of consecutive cases of confirmed acute maternal infections; series of subsequent serum samples, homogeneous methods, and accurate expertise to determine GA at maternal infection; and systematic postnatal follow-up to confirm congenital infection and ascertain the clinical outcomes in infected children [15] [16] [17] [18] . One study was based on 603 maternal and 161 fetal infections diagnosed and managed in our department between 1988 and 1996 [16] . Its findings have been widely used for the management of pregnant women and children with Toxoplasma infection but were based on data that was collected before polymerase chain reaction (PCR) tests were routinely used on amniotic fluid to detect T. gondii DNA for diagnosis and, mostly, before 1992 when monthly retesting became mandatory for susceptible pregnant women in France. Risk curves were also established from the European Multicenter Study on Congenital Toxosplasmosis (EMSCOT) [17, 19] and the Systematic Review on Congenital Toxoplasmosis (SYROCOT) [18] data, but heterogeneity of screening and treatment protocols across centers limited the interpretability of their findings. The need for estimates taking into account current possibilities for managing maternal and congenital infections led us to extend our original cohort. We now present updated findings based on 2048 cases of maternal infection and 513 cases of congenital infection. Subsamples of mother-child pairs identified from 1987 to 2002 were described in earlier publications [16, [20] [21] [22] [23] [24] . The present report permits comparisons of possibilities and outcomes over different timeframes.
METHODS
The study was based on an observational cohort that included all pregnant women diagnosed with acute Toxoplasma infections at our reference laboratory of Lyon (France) between 1987 and December 2008 (Figure 1 ). Differences over the study period were analyzed to test (1) whether implementing a mandatory monthly retesting in 1992-instead of the previous nonspecified recommendations for screening-had reduced the risks of congenital infection by allowing a more rapid introduction of treatment, and (2) whether the availability of PCR on amniotic fluid since 1995 had reduced the risk of clinical signs by leading to earlier treatment of infected children with pyrimethamine and sulfadiazine (PS).
The protocols for case identification and for data collection are unchanged since 1987. Acute maternal Toxoplasma infection was defined as a change from negative to positive specific immunoglobulin G (IgG) antibodies or a significant increase in IgG with concomitant high immunoglobulin M (IgM) titers. All samples were tested for Toxoplasma IgM and IgG antibodies using commercial tests, and the results classified as positive or negative according to the manufacturers' cutoffs (Supplementary Data A). All dates of maternal infection were established prior to any prenatal investigation and are therefore blind to the pregnancy outcome. Antenatal diagnosis, offered for infections acquired between 5 and 32 weeks of gestation, used mice inoculation with fetal blood and amniotic fluid as standard tests until December 1995, and PCR and mice inoculation of amniotic fluid after that time. Medical pregnancy terminations were only performed when severe fetal lesions were detected during monthly fetal ultrasound examinations. Treatment of maternal infection was unchanged throughout the study period (Supplementary Data B) ; however, prior to 1996, PS was alternated with spiramycin every 3 weeks and after 1996 PS was taken continually.
All newborns underwent head ultrasonography and indirect ophthalmologic examination of the retina and were tested for specific anti-Toxoplasma IgM, immunoglobulin A, and IgG between 3 and 10 days of life and every 2-3 months for at least 1 year. Over the entire study period, congenital toxoplasmosis was defined as the persistence after the first year of life of specific IgG (>5 IU/mL) using indirect immunofluorescence (Toxospot IF, bioMérieux). Positive parasitological or histological findings on postmortem examination of fetal tissue were considered to be diagnostic. The case definition for the absence of congenital infection is a decrease in IgG using indirect immunofluorescence to <5 IU (limits of detection) before 1 year of age in the absence of treatment. Infected newborns received PS for 12-14 months and were followed up without age limits (see Supplementary Data C).
Information about infected women and their children were collected routinely at the Lyon reference laboratory and at the adjacent outpatient clinic. When necessary, additional data were collected from obstetricians, pediatricians, or/and ophthalmologists ( Figure 1 ). According to French legislation, parents were informed that the data collected could be used in research studies unless they refused. To date no refusal was recorded. The French Commission Nationale de l'Informatique et des Libertés was notified of the database (reference: HCL0602), and the study was authorized by the hospital ethics committee.
The present study population included all pregnant women referred to our center between April 1987 and December 2008. We excluded those who were referred specifically for suspected fetal infection or had been infected prior to conception or for whom GA at maternal infection could not be estimated. Fetuses or children for whom congenital infection could neither be confirmed nor ruled out were also excluded ( Figure 2 ).
Logistic regression was used to assess the effects of GA at the time of maternal infection, and of calendar periods, on the risk of congenital infection. The possibly nonlinear relationship between GA and risk was modeled using a flexible cubic regression spline approach [25] [26] [27] . The results were then transformed into probabilities of congenital infection, corresponding to maternal infections at different GA, and 95% confidence intervals (CIs) were estimated using the nonparametric bootstrap technique [28] . Differences between the risks of congenital infection were tested before vs after mid-1992, while adjusting for GA at the time of maternal infection. When period effect was statistically significant, probabilities of congenital infection for maternal infections at specific GA were reported for the most recent period. A similar approach was used to assess the effects of GA at the time of maternal infection, and of calendar periods, on the risk of clinical signs at 3 years of age. The analyses were replicated on 2 samples of children (all live births and only those with congenital infection); risks were compared for maternal infections diagnosed before and after December 1995, when PCR testing on amniotic fluid became available. Two-tailed α = .05 was used as a criterion for statistical significance. Analyses were performed using Stata software, version 10.0 (StataCorp) and R software 2.10.0 (http://cran. univ-lyon1.fr/).
RESULTS

Characteristic of Total Population
A total of 2361 pregnant women were diagnosed with an acute Toxoplasma infection between April 1987 and December 2008. Of these, 286 (12.1%) were excluded, leaving 2075 pregnancies ( Figure 2 ). Twenty-seven second-born twins were excluded to avoid intrafamilial correlation, leaving 2048 mother-child pairs for analysis. Mean maternal age at conception was 29 years (±5 years [range, 16-48 years]), no mother was known to suffer from immune deficiency. Among the 2040 women with information on antiparasitic treatment, 93.2% received some treatment (spiramycin alone for 85.0%, or at least 1 course of PS for 15.0%). Less than 7.0% (n = 139) of infected mothers received no treatment, mainly because their infection was not diagnosed before delivery (n = 106; 76.0%). There were 18 
Probabilities of Congenital Infection
Probabilities of congenital infection were significantly lower after mid-1992 (46.6% vs 59.4% at 26 GA weeks; P = .038), when monthly retesting became mandatory for all susceptible pregnant women in France (Table 1 , Supplementary Data D). This change in screening was associated with faster initiation of antenatal treatment after mid-1992 (P < .001): the median delay until treatment was reduced by 4 days (95% CI, −.6 to 8.6; 33 vs 37 days; P = .0007) in the first trimester, by 6 days (95% CI, 2.1-9.9; 33 vs 27 days; P = .0004) in the second trimester, and by 8 days (95% CI, 3.2-12.8, 28 vs 20 days; P = .0001) in the third trimester.
Risk estimates for congenital infection were therefore based on the 1624 maternal infections diagnosed after mid-1992. Probabilities of congenital infection were <10% for maternal infections before 12 weeks of gestation, rose sharply to 20.0% at 19 weeks, and then continued increasing to 52;3%, 62.8%, and almost 70% at 28, 35, and 39 GA weeks, respectively (Table 2, Figure 3 ). Table 3 compares the outcomes across the trimesters of gestation at the time of maternal infection.
Probabilities of Clinical Signs at 3 Years of Age
The proportion of live-born infected children who were recognized as being infected antenatally was larger after 1995 (87/ 272 [32.0%]) than before 1995 (46/213 [21.6%]; P = .011). Probabilities of clinical signs in live-born children (either uninfected or if infected followed for 3 years) were significantly lower in infected children born from mothers diagnosed after 1995 than before 1995 (46/1150 vs 87/794; odds ratio = 0.59 [95% CI, .40-.89]; P = .012; Table 1 , Supplementary Data E). Probabilities of clinical signs at 3 years of age were, thus, estimated using the 1150 live-born children whose mothers were diagnosed with acute infection after December 1995. The estimated risks of clinical signs increased with increasing GA at the time of maternal infection, from <1% in the first month, to 7% between 20 and 27 weeks; and slightly decreased thereafter, to about 6% for infections closer to delivery (Table 2) . Among the 207 infected live-born children, the estimated risks were the highest for maternal infections that occurred in the first 15 weeks of pregnancy and decreased with each additional month to a minimum of 9.5% for infections immediately before delivery (Table 2) . Clinical signs were mostly retinochoroiditis and intracranial calcifications (Table 4) .
DISCUSSION
The aim of our study was to provide precise and updated information on the consequences of Toxoplasma infection during pregnancy, in terms of the probability of fetal infection and clinical signs at age 3. Unlike previous studies [17] [18] [19] , this study collected data at the same center, with homogeneous selection criteria and the same biological techniques to determine the date of maternal contamination and efforts to limit loss to follow-up (<6%).
Because of the extended recruitment period and to ensure reliable predictions, we tested whether a period effect existed due to changes in screening and in the diagnosis of fetal toxoplasmosis. Given the unchanged process for case identification, it is unlikely that many cases of fetal infection were missed over the study period. The use of real-life data might have led us to underdetect some clinical signs, mainly in the earlier years, but this would only underestimate the reduction in sequelae. We thus provide estimates for the most recent periods only.
Analysis of our data provides several findings useful for the practical day-to-day management of seroconversion, whether detected through universal or individual screening.
First, mother-to-fetus transmission is far from being consistent, even during the third trimester. Second, severe symptoms are rare: The majority of infected infants were healthy; only 22% had some clinical sign at age 3 years. Pregnancy terminations were rare and spread uniformly over the study period and did not account for improvements in outcomes.
Therefore, our message is that maternal Toxoplasma infection should never automatically lead to termination, even when it occurs early in pregnancy. On the contrary, fetal ultrasound monitoring should be carried out regularly to reassure the parents of the absence of severe symptoms, and regular postnatal follow-up should be provided.
The second recommendation is to perform amniocentesis whenever possible, even in cases of early contamination, because the risk of associated infection is at least equivalent to that of amniocentesis. Because of the excellent performance of real-time PCR techniques that target the 529-bp DNA fragment of T. gondii [29] , a negative result is associated with a low likelihood that infection has occurred [24] , making it possible to reassure the parents and to avoid pregnancy termination and unnecessary PS treatment. This may concern as many as 50% of cases up to 28 weeks of gestation, >40% up to 33 weeks of gestation, and 30% at the end of pregnancy. In contrast, when PCR gives positive results, PS treatment can be offered and ultrasound monitoring can be intensified. When severe fetal lesions are detected, termination can be envisaged. Intensive treatment with PS without fetal infection confirmation would then be reserved for cases of late maternal infection where amniocentesis is not possible. Another reason for identifying infected fetuses before birth is to enable postnatal treatment to be initiated early after birth. It also allows parents to receive early explanations of the importance of prolonged postnatal follow-up. Our data confirm the necessity of this follow-up, because 22% of the infants had ocular lesions at 3 years of age, one-third of which were first detected after 1 year. Longer-term studies have shown that despite postnatal treatment, the probability that these lesions will recur is not negligible, and new lesions may occur subsequently [5-8, 30, 31] , but that, despite this unforeseeable evolution, repercussions on visual function and quality of life are rare [32] .
Another important finding in our cohort was the ability to compare outcomes coincident with changes in management. Abbreviations: PCR, polymerase chain reaction; PS,pyrimethamine and sulfadiazine. Specifically, there was a decrease in fetal infection after 1992 and a reduction in sequelae after 1995.
It is possible to envision other causes of this evolution, but the factor most likely to be causal is that the introduction of mandatory monthly screening in 1992 played a significant role in reducing fetal infection during the second and third trimesters by allowing a larger proportion of women to be treated within 21 days, which in the SYROCOT study was associated with a 48% risk reduction [18] . Most infections occurring early in pregnancy were already detected through the test required before the end of the first trimester since 1985. This could explain the fact that monthly retesting did not reduce the risk associated with these infections.
With regard to the reduction in severity of lesions after 1995, it is most likely that it is due to the advent at that time of PCR techniques for analyzing amniotic fluid, allowing the screening and treatment of a greater number of infected fetuses in utero. It also coincides with the cessation at our center of the 3-week regimens of PS with spiramycine following a positive antenatal diagnosis in favor of continuous PS treatment up until delivery. Studies are under way at our center to determine whether this reduction in risk also applies to late ocular lesions. Our findings will require independent replication, but if our hypotheses concerning early treatment of maternal and fetal infections are confirmed, they would provide important evidence for the efficacy of prenatal screening.
The experience in toxoplasmosis gained in France over the past 20 years by perinatal professionals, as well as the total reimbursement of medical costs, has probably had a positive impact on the quality of care. However, we cannot exclude a diminution of parasite virulence over time, concomitantly or in association with the decreased prevalence noted in France [33] and worldwide [34] , even if there is no evidence that parasite genetics have changed in France during this time [32] . The question of the virulence of various Toxoplasma strains should also be taken into consideration when extrapolating from our results and those of future studies aimed at investigating treatment efficacy. It has been demonstrated that genotype II strains, which are the most prevalent in France [35] and in the rest of Europe and also exist in the United States [36, 37] , are associated with less severe disease and prematurity than other strains [35, 39] . Results in North America seem similar to the favorable effects of prenatal treatment in France. Specifically, whereas severity was different between genotype II and nongenotype II infections at birth without prenatal treatment, with prenatal treatment the differences were not present [38] . The same appeared to be the case for later manifestations for those treated in the first year of life [35] . Therapeutic effects might not be extrapolatable to other epidemiological contexts, such as in South America, even though all T. gondii tested, including those found in Brazil, have had similar dihydrofolate synthase enzymes-without mutations that would suggest resistance to anti-folate medications [40] and no differences in sensitivity of South American or African T. gondii to anti-folate or other medicines have been demonstrated to date. In the absence of proof of efficacy in all settings, our data should be used with caution in managing patients from regions where more-virulent strains predominate. However, it would seem that there is an even greater likelihood of benefit for prompt treatment, as damage appears to be more severe, and early data suggest such benefit [35, 40] .
A second limitation of our data is linked to the limited postnatal follow-up in our study. Our estimates did not include lesions (essentially ocular) that are liable to occur after 3 years of age. In contrast, they contain precise information on the risks of neurological lesions (less liable to occur after age 3) that are of greater concern to parents. The ability to provide precise information to parents on this subject thus responds to the importance of avoiding excessive anxiety and recourse to unjustified termination of pregnancy.
In conclusion, our results indicate that the consequences, in terms of transmission and sequelae, in women whose infection is identified and treated early in pregnancy are rarely severe. They also provide valuable insights on the benefits of prenatal screening, in agreement with the conclusions of recent studies [5, 35, 41, 42] . Our findings support changes in practice where antenatal screening is not now implemented. They will be useful for the ongoing assessment of antenatal screening efficiency.
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